pharmaphorum

AUGUST 4, 2022

Unlocking the secrets of the human genome has long been an ambitious pursuit for researchers around the world. Today, the landscape of genomic testing and research is rapidly progressing, with significant scientific and technological advances driving a paradigm shift in the understanding of oncology at a molecular level.

Genome 52

Genome Genomics Genome Project DNA 52

The Pharma Data

MARCH 7, 2022

By combining CRISPR technology with a protein designed with artificial intelligence (AI), it is possible to awaken individual dormant genes by disabling the chemical “off switches” that silence them. PRC2 can be blocked with chemicals, but they are imprecise, affecting PRC2 function throughout the genome. it can be reawakened.

Protein 52

Protein Gene Genome Genomics 52

The Pharma Data

SEPTEMBER 25, 2020

. Monte Rosa Therapeutics has raised $96m in Series B financing to support further develop of its pipeline of small-molecule protein degraders. The company, which was originally formed as a spinout from Cancer Research UK-funded research at the Institute of Cancer Research, specialises in targeted protein degradation.

Protein 40

Protein Development Genome Genomics 40

pharmaphorum

SEPTEMBER 16, 2022

A mere six months ago Verily launched the study with Sosei Heptares – a global leader in GPCR structure-based drug design – with an aim to “prioritise protein targets for therapeutic targeting in immune-mediated disease”. Kim recognised then, he said, that better tools for medicine needed to be developed, and that they still do.

Development 135

Development Research Drugs Clinical Trials 135

Drug Discovery World

APRIL 19, 2023

Scientists at The Institute of Cancer Research, London, are teaming up with small molecule neoantigen immuno-oncology company NeoPhore to develop new potential cancer drugs. Credit: Julia Sero/ICR The post Immuno-oncology collaboration to develop new type of cancer drug appeared first on Drug Discovery World (DDW).

DNA 98

DNA Development Drugs Genome 98

pharmaphorum

MAY 12, 2022

Bristol-Myers Squibb’s Celgene unit has clearly been impressed by progress in its four-year-old alliance with Evotec on protein degradation. These small drug compounds destabilise proteins by bringing them into proximity with enzymes called E3 ubiquitin ligases that cause them to be broken down. billion partnership last week. .

Protein 52

Protein Genome Genomics Drugs 52

Pharmaceutical Technology

JUNE 23, 2022

Mpro has become the main focus of intense research and treatment development as it is vital for viral replication. It functions as a molecular scissor by slicing long chains of virus’ polypeptide proteins into smaller component proteins. These smaller segments can subsequently fold and develop to create new virus particles.

Drugs 130

Drugs Protein Genome Genomics 130

Drug Discovery World

JANUARY 26, 2023

This is the latest episode of the free narrated DDW podcast, “CRO’s and targeted protein degradation offer an exciting future”. They are called “ CROs: Drug discovery expertise on hand ” and “ Why the emergence of targeted protein degradation is so exciting ”.

Protein 52

Protein Drugs Research Marketing 52

The Pharma Data

MARCH 15, 2022

The p53 protein protects our cells from cancer and is an interesting target for cancer treatments. Researchers at Karolinska Institutet in Sweden have now found an unusual way of stabilising the protein and making it more potent. Researchers around the world are therefore trying to develop cancer treatments that in some way target p53.

Protein 52

Protein Research Genetics DNA 52

The Pharma Data

MARCH 23, 2022

Polymerase is a viral protein that directs how Ebola virus replicates its genome as it infects new hosts. The researchers discovered that Ebola virus polymerase hijacks a cellular protein called GSPT1. To treat Ebola virus infections, researchers are taking a close look at a key piece of the virus: polymerase.

Protein 52

Protein Genome Genomics Research 52

Drug Discovery World

OCTOBER 2, 2023

X-Chem and the Structural Genomics Consortium (SGC) have entered a collaboration aimed at creating new chemical tools to study human proteins. Under the agreement, X-Chem will use its DEL platform to create datasets for proteins chosen and supplied by the SGC, which will be posted to a public portal to be used for model building.

Genome 52

Genome Genomics Protein DNA 52

Pharmaceutical Technology

FEBRUARY 15, 2023

Innovation S-curve for the pharmaceutical industry CRISPR nuclease is a key innovation area in pharmaceutical development CRISPR, which refers to clustered regularly interspaced short palindromic repeats, are bacteriophage-derived DNA sequences that had previously infected the prokaryote and are found in the genomes of bacteria and archaea.

In-Vivo 162

In-Vivo Genome Genomics Gene Editing 162

Bioengineer

JANUARY 16, 2024

This mutation hinders the drug’s binding to the mutant EGFR protein. Osimertinib, however, can covalently bind to the T790M and cysteine-797 (C797) residue at the protein’s ATP binding site, overcoming resistance mechanisms. T790M loss has been linked to earlier resistance and poorer survival in other cohorts.

Genome 119

Genome Genomics Protein In-Vitro 119

pharmaphorum

FEBRUARY 25, 2022

A new stem cell model, discovered by researchers exploring the human genome, will help scientists to map out the key genomic changes during early development. Prior to this latest development, research into the human ZGA was limited to human embryos at a later stage of growth, under stringent UK regulations.

Research 69

Research Genome Genomics Protein 69

Drug Discovery World

AUGUST 21, 2023

SBIR fast-track grant from the NIH to apply its proprietary Multiplexed Assays for the Rational Modulation Of Transcription Factors (MARMOT) platform to their deep learning AI model and accelerate the development of transcription factor drugs. Talus Bio was also awarded a $2.0M The post $4.3

Drugs 98

Drugs Gene Expression Protein Gene 98

Pharmaceutical Technology

JULY 5, 2022

Researchers at the UNC School of Medicine have discovered that hepatitis A virus (HAV) replication needs particular interactions between the human protein ZCCHC14 and TENT4 poly(A) polymerases, a group of enzymes. HAV usually hijacks TENT4 and utilises it for the replication of its own genome.

Protein 130

Protein RNA Genome Genomics 130

Scienmag

AUGUST 11, 2020

Researchers from Skoltech, Lomonosov Moscow State University, and the Kharkevich Institute for Information Transmission Problems have studied the genomes of some 200 strains of bacteria to determine which proteins in the ribosome, part of the key cell machinery, can be safely lost and why.

Bacteria 41

Bacteria Genome Genomics Protein 41

XTalks

MAY 10, 2022

On Saturday, researchers at the Children’s Hospital of Philadelphia (CHOP) have announced that they developed and launched a new bioinformatics software tool called CancerVar (cancer variant interpretation). Why Was CancerVar Developed? What is CancerVar? This software is implemented in Python and has a user-friendly web server.

Bioinformatics 98

Bioinformatics Development Gene Genome 98

Drug Discovery World

NOVEMBER 14, 2022

A collaboration between PerkinElmer’s SIRION Biotech business and the Centre for Genomic Regulation (CRG) agreed to jointly develop new generation adeno-associated virus (AAV) vectors for type 1 and type 2 diabetes gene therapy in the pancreas. . Find out more: Collaboration to develop AAV vectors for diabetes gene therapy .

Development 52

Development Gene Therapy Drugs Gene 52

Drug Discovery World

OCTOBER 6, 2023

In celebration of the Nobel Prize for Medicine going to two of the early proponents of mRNA technology for creating therapeutics, Katalin Karikó and Drew Weissman, this week our round-up highlights the importance of genetics, genomics and gene editing in drug discovery.

Drugs 52

Drugs Gene Editing Genome Genomics 52

Drug Discovery World

FEBRUARY 7, 2024

Professor Jonathan Blackburn, Chief Scientific Officer (CSO) of Sengenics, featured in a sponsored DDW Sitting Down With podcast to discuss the advantages of functional protein microarrays, challenges to overcome for biomarker discovery, Sengenics’ new i-Ome Discovery chip, and more. He elaborates in the podcast.

Medicine 57

Medicine Protein FDA Approval DNA 57

Pharmaceutical Technology

JANUARY 25, 2023

PXL770 is a new, first-in-class direct activator of adenosine monophosphate-activated protein kinase (AMPK). It has been developed to treat autosomal dominant polycystic kidney disease (ADPKD) and ALD, in rare diseases.

Drugs 130

Drugs Genome Genomics Medicine 130

Drug Discovery World

NOVEMBER 14, 2023

A Phase Ib trial has shown low-density lipoprotein cholesterol (LDL-C) reductions up to 55% and blood PCSK9 protein reductions up to 84% after a single infusion of Verve Therapeutics’ Verve-101. Since the mutation only affects a single gene, it makes it a prime candidate for genome editing treatments.

In-Vivo 52

In-Vivo Gene Editing Gene Genome 52

Drug Discovery World

NOVEMBER 27, 2023

Across the biotherapeutics workflow The landscape of large molecule drug development has evolved significantly in recent decades. Technological innovations supporting discovery and development stages have concentrated on both upstream and downstream aspects of the workflow. This article is sponsored by Revvity.

Production 57

Production Engineer Gene Editing Gene 57

XTalks

AUGUST 5, 2020

Single cell RNA sequencing technology has been extensively applied to understand heterogeneity among tumor cells, within the tumor microenvironment and during cell development. 10x Genomics’ chromium single cell solutions are designed to accommodate a wide range of single cell or nuclei suspensions as a starting sample.

Gene Expression 112

Gene Expression Development RNA Drugs 112

Drug Discovery World

OCTOBER 26, 2023

The technologies cover the whole range of biomolecules from genes to protein to metabolites. While we are using standard commercially available processes for genomics, we have invested massively into high-throughput and high-resolution transcriptomics, proteomics, and metabolomics methods. phosphorylations or ubiquitinations).

Drugs 52

Drugs Protein Genome Genomics 52

Drug Discovery World

MARCH 26, 2024

DDW’s Megan Thomas caught up with Oliver Rausch, Chief Scientific Officer at Storm Therapeutics, following the ESMO Targeted Anticancer Therapies Congress 2024, a global meeting focusing on promising new anticancer targets and agents, focusing on those in early phase clinical development. MT: What’s next for STORM’s research?

RNA 62

RNA In-Vivo In-Vitro DNA 62

Drug Discovery World

JANUARY 21, 2024

Advances in this area are having a positive effect on both the commercial success of drug discovery and development organisations, as well as benefitting the health and wellbeing of the global population. Technology plays multiple roles in all stages of vaccine development,” says Kanekiyo. “It

Protein 52

Protein Vaccination Vaccine Development 52

Drug Discovery World

NOVEMBER 1, 2022

Researchers say they have successfully used a cell’s natural process for making proteins to ‘slide’ genetic instructions into a cell and produce critical proteins missing from those cells. . Two methods currently used to deliver protein-making packages into cells, ‘mini promoters’ and serotype-mediated gene expression, vary widely.

Gene Expression 52

Gene Expression Gene Packaging Packaging 52

The Pharma Data

DECEMBER 16, 2020

Evotec and Bristol Myers Squibb (the successor in interest to Celgene ) initiated their long-term strategic drug discovery and development partnership in the field of targeted protein degradation in 2018 with the goal to identify novel drug targets.

Protein 40

Protein Containment Bioinformatics Drugs 40

Pharmaceutical Technology

DECEMBER 9, 2022

M&A – Commended PRODUCT LAUNCHES – Commended RESEARCH AND DEVELOPMENT – Commende d. Solvias is a Swiss-based pharmaceutical company focused on contract research, development and manufacturing. Pharmaceutical Technology Excellence Rankings – The Verdict. Integrated analytical services for pharmaceuticals.

Development 130

Development Manufacturing Production Vaccination 130

The Pharma Data

DECEMBER 17, 2020

Lupus causes the production of proteins called autoantibodies in the immune system, which attack tissues and organs, including the kidneys. Farber extended congratulations to GSK on behalf of the alliance: “An effective treatment developed specifically for lupus nephritis has been desperately needed. MacroGenics Inc.

FDA Approval 52

FDA Approval Genome Genomics Production 52

XTalks

OCTOBER 20, 2023

Clinical-stage genome editing company Intellia Therapeutics has received clearance from the US Food and Drug Administration (FDA) for its Investigational New Drug (IND) application to start a pivotal phase III trial of NTLA-2001 for the treatment of transthyretin (ATTR) amyloidosis with cardiomyopathy.

In-Vivo 52

In-Vivo Gene Editing Trials Gene 52

pharmaphorum

OCTOBER 12, 2022

Overall, the aim is to improve the efficiency of drug discovery by identifying genetic variants that contribute to human disease in omics data – a broad category that includes DNA profiles, gene transcripts, and protein expression.

Genome 65

Genome Genomics DNA Drugs 65

Drug Discovery World

MARCH 2, 2023

A new paper has solved the 20-year mystery of how epigenetic modifications act as traffic lights to control gene expression and could ultimately speed up the development of a new class of epigenetic cancer drugs. Epigenetics is still largely unexplored and referred to as the ‘dark matter’ of the genome.

Gene Expression 52

Gene Expression Gene DNA RNA 52

XTalks

OCTOBER 21, 2020

The answer may lie in the genetic code of the virus, which scientists at Duke University have found contains several silent mutations that affect protein folding. The researchers focused on the spike proteins that protrude from the surface of the coronavirus, which are responsible for viral attachment and entry into host cells.

RNA 98

RNA Protein Genome Genomics 98

Drug Discovery World

JUNE 5, 2023

New approaches to partnering In this event in the Biotech track, Clive Cookson, Science Editor at the Financial Times, interviewed John McDonald, Corporate Vice President, Global R&D Business Development, Novo Nordisk. The discussion answered three main questions: What is the new direction for the company? How to improve its pipeline?

Genome 52

Genome Genomics Life Science Genetics 52